RTP-based Tranzyme Pharma (www.tranzyme.com), a developer of drugs to treat gastrointestinal and metabolic disorders, has received a European patent covering part of its drug discovery technology. The process received a U.S. patent earlier this year.
The patent protects key aspects of the Company’s core drug discovery technology, Macrocyclic Template Chemistry (MATCH™). MATCH™ is based on the synthesis of specific types of low-molecular weight, drug-like compounds called macrocycles.
Tranzyme Pharma is a CED member.